Literature DB >> 24938594

Is plasma C3 and C4 levels useful in young cerebral ischemic stroke patients? Associations with prognosis at 3 months.

Bin Zhang1, Ning Yang, Cong Gao.   

Abstract

Plasma complement C3 and C4 act as risk factor for vascular diseases related to atherosclerosis. The association C3 and C4 levels in young ischemic stroke patients with the prognosis were still not unknown. We conducted this study to establish the significance of admission C3 and C4 levels as a possible predictor of 3 months prognosis in young patients with acute ischemic stroke. We conducted this study in 1,451 young Chinese patients as determined by the modified Rankin Scale at 3 months. Bivariate logistic regression analyses were used to determine the risk factors of outcome in male and female patients. Stepwise logistic regression analysis confirmed only the lowest quartile of C3 level (0.17-0.90 g/L) was independently associated with prognosis in male patient after adjustment the confounding risk factors of stroke [0.558 (0.382-0.815); P = 0.003], but not the association for plasma C4 levels. Meanwhile, serum SUA and WBC concentrations, TIA history are typically related to prognosis at 3 months after acute ischemic stroke. Our analysis does provide compelling information regarding the baseline complement C3 levels in young ischemic stroke patients as possible predictors of early prognosis after 3 months of acute phase. Thus, our results must be seen as a hypothesis only and will have to be confirmed in larger trials.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 24938594     DOI: 10.1007/s11239-014-1100-7

Source DB:  PubMed          Journal:  J Thromb Thrombolysis        ISSN: 0929-5305            Impact factor:   2.300


  27 in total

1.  Complement C3 and C-reactive protein levels in patients with stable coronary artery disease.

Authors:  Ramzi Ajjan; Peter J Grant; Timothy S Futers; Jane M Brown; Charlotte M Cymbalista; May Boothby; Angela M Carter
Journal:  Thromb Haemost       Date:  2005-11       Impact factor: 5.249

2.  Complement C3 and C-reactive protein are elevated in South Asians independent of a family history of stroke.

Authors:  Riyaz Somani; Peter J Grant; Kirti Kain; Andrew J Catto; Angela M Carter
Journal:  Stroke       Date:  2006-06-29       Impact factor: 7.914

3.  Plasma C3 and C3a levels in cryptogenic and large-vessel disease stroke: associations with outcome.

Authors:  Anna Stokowska; Sandra Olsson; Lukas Holmegaard; Katarina Jood; Christian Blomstrand; Christina Jern; Marcela Pekna
Journal:  Cerebrovasc Dis       Date:  2011-06-28       Impact factor: 2.762

4.  The alternative complement pathway propagates inflammation and injury in murine ischemic stroke.

Authors:  Andrew Elvington; Carl Atkinson; Hong Zhu; Jin Yu; Kazue Takahashi; Gregory L Stahl; Mark S Kindy; Stephen Tomlinson
Journal:  J Immunol       Date:  2012-10-01       Impact factor: 5.422

5.  Systemic complement depletion diminishes perihematomal brain edema in rats.

Authors:  G Xi; Y Hua; R F Keep; J G Younger; J T Hoff
Journal:  Stroke       Date:  2001-01       Impact factor: 7.914

6.  Complement C3 is a risk factor for the development of diabetes: a population-based cohort study.

Authors:  Gunnar Engström; Bo Hedblad; Karl-Fredrik Eriksson; Lars Janzon; Folke Lindgärde
Journal:  Diabetes       Date:  2005-02       Impact factor: 9.461

7.  The alternative and terminal pathways of complement mediate post-traumatic spinal cord inflammation and injury.

Authors:  Fei Qiao; Carl Atkinson; Mark S Kindy; Anandakumar Shunmugavel; B Paul Morgan; Hongbin Song; Stephen Tomlinson
Journal:  Am J Pathol       Date:  2010-10-15       Impact factor: 4.307

8.  In situ deposition of complement in human acute brain ischaemia.

Authors:  E D Pedersen; E M Løberg; E Vege; M R Daha; J Maehlen; T E Mollnes
Journal:  Scand J Immunol       Date:  2009-06       Impact factor: 3.487

9.  Classification of subtype of acute ischemic stroke. Definitions for use in a multicenter clinical trial. TOAST. Trial of Org 10172 in Acute Stroke Treatment.

Authors:  H P Adams; B H Bendixen; L J Kappelle; J Biller; B B Love; D L Gordon; E E Marsh
Journal:  Stroke       Date:  1993-01       Impact factor: 7.914

10.  High expression of complement components in omental adipose tissue in obese men.

Authors:  Britt G Gabrielsson; Jenny M Johansson; Malin Lönn; Margareta Jernås; Torsten Olbers; Markku Peltonen; Ingrid Larsson; Lars Lönn; Lars Sjöström; Björn Carlsson; Lena M S Carlsson
Journal:  Obes Res       Date:  2003-06
View more
  4 in total

Review 1.  Injury site-specific targeting of complement inhibitors for treating stroke.

Authors:  Ali Alawieh; Stephen Tomlinson
Journal:  Immunol Rev       Date:  2016-11       Impact factor: 12.988

2.  Complement C3a Receptor (C3aR) Mediates Vascular Dysfunction, Hippocampal Pathology, and Cognitive Impairment in a Mouse Model of VCID.

Authors:  Kanchan Bhatia; Adam Kindelin; Muhammad Nadeem; Mohammad Badruzzaman Khan; Junxiang Yin; Alberto Fuentes; Karis Miller; Gregory H Turner; Mark C Preul; Abdullah S Ahmad; Elliott J Mufson; Michael F Waters; Saif Ahmad; Andrew F Ducruet
Journal:  Transl Stroke Res       Date:  2022-03-08       Impact factor: 6.800

Review 3.  Complement in the Homeostatic and Ischemic Brain.

Authors:  Ali Alawieh; Andrew Elvington; Stephen Tomlinson
Journal:  Front Immunol       Date:  2015-08-12       Impact factor: 7.561

4.  Proteomics-Based Identification of Diagnostic Biomarkers Related to Risk Factors and Pathogenesis of Ischemic Stroke.

Authors:  Jiyeong Lee; Arum Park; Sora Mun; Hyo-Jin Kim; Hyunsong Son; Hyebin Choi; Doojin Kim; Soo Joo Lee; Jae Guk Kim; Hee-Gyoo Kang
Journal:  Diagnostics (Basel)       Date:  2020-05-25
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.